Preclinical antitumor activity of the orally available heat shock protein 90 inhibitor NVP-BEP800

Molecular Cancer Therapeutics

Volumn 9, Issue 4, 2010, Pages 906-919

  Massey, Andrew J ^a   Schoepfer, Joseph ^b   Braugh, Paul A ^a   Brueggen, Josef ^b   Chène, Patrick ^b   Drysdale, Martin J ^a   Pfaar, Ulrike ^b   Radimerski, Thomas ^b   Ruetz, Stephan ^b   Schweitzer, Alain ^b   Wood, Mike ^a   Garcia Echeverria, Carlos ^b   Jensen, Michael Rugaard ^b  

^a Vernalis PLC   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; CASPASE 3; CASPASE 7; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; NVP BEP 800; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SENSITIVITY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; HUMAN; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR CELL LINE; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; APOPTOSIS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; ISOXAZOLES; MICE; MICE, NUDE; PROTEIN PROCESSING, POST-TRANSLATIONAL; PYRIMIDINES; RESORCINOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77950807945     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0055     Document Type: Article

References (37)

1. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17:2225-2235
2. Koga F, Kihara K, Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009;29:797-807.
3. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113: 202-216 (Pubitemid 350015011)
4. Drysdale MJ, Brough PA, Massey A, Jensen MR, Schoepfer J. Targeting Hsp90 for the treatment of cancer. Curr Opin Drug Discov Devel 2006;9:483-495
5. Gao Z, Garcia-Echeverria C, Jensen MR. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy. Curr Opin Drug Discov Devel 2010;13:193-202.
6. Dutta R, Inouye M. GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 2000;25:24-28
7. Dollins DE, Warren JJ, Immormino RM, Gewirth DT. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol Cell 2007;28:41-56.
8. Saibil HR. Chaperone machines In action. Curr Opin Struct Biol 2008; 18:35-42.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100: 57-70.
10. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002;2: 3-24. (Pubitemid 34462457)
11. Pratt WB, Toft DO. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 2003;228:111-133 (Pubitemid 36187918)
12. Taldone T, Gozman A, Maharaj R, Chiosis G. Targeting Hsp90: smallmolecule inhibitors and their clinical development. Curr Opin Pharmacol 2008;8:370-374
13. Egorin MJ, Zuhowskl EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17(allylamlno)-17- demethoxygeldanamycin (NSC 330507) In CD2F1 micel. Cancer Chemother Pharmacol 2001;47:291-302. (Pubitemid 32640768)
14. Glaze ER, Lambert AL, Smith AC, et al. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 2005; 56:637-647
15. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;36:305-315
16. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of 17-allylamino-17 demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007;13:1775-1782 (Pubitemid 46952945)
17. Guo W, Relgan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxldoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res 2005;65:10006-10015 (Pubitemid 41541482)
18. Guo W, Relgan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bloreduction of a series of benzoquinone ansamycins by NAD(P)H: quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol 2006;70: 1194-1203 (Pubitemid 44435970)
19. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DTDiaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91:1940-1949
20. Gaspar N, Sharp SY, Pacey S, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009;69:1966-1975.
21. Brough PA, Barril X, Borgognoni J, et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009;52:4794-4809
22. Brough PA, Aherne W, Barril X, et al. 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51:196-218.
23. Schilb A, Riou V, Schoepfer J, et al. Development and implementation of a highly miniaturized confocal 2D-FIDA-based highthroughput screening assay to search for active site modulators of the human heat shock protein 90β. J Biomol Screen 2004;9:569-577 (Pubitemid 40503515)
24. Chene P, Rudloff J, Schoepfer J, et al. Catalytic inhibition of topolsomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 2009;9:1.
25. Smith V, Sausvllle EA, Camaller RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins In melanoma models. Cancer Chemother Pharmacol 2005;56:126-137
26. Jensen MR, Schoepfer J, Radlmerski T, et al. NVP-AUY922: a small molecule HSP90 Inhibitor with potent antitumor activity in preclinical breast cancer models. Breast Cancer Res 2008;10:R33.
27. Hamaoka T. Autoradiography of new era replacing traditional X-ray film. Cell Technology 1990;9:456-462
28. Ullberg S. The technique of whole-body autoradiography: cryosectioning of large specimens. Sweden: LKB-Producter AB; 1977.
29. 14C-whole-body autoradlograms. Int J Rad Appl Instrum A 1987;38:329-333
30. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973;51:1417-1423
31. Gershwin ME, Ikeda RM, Kawakami TG, Owens RB. Immunobiology of heterotransplanted human tumors In nude mice. J Natl Cancer Inst 1977;58:1455-1461 (Pubitemid 8094252)
32. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size In afnymlc (nude) mice. Cancer Chemother Pharmacol 1989;24:148-154
33. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008;68:2850-2860 (Pubitemid 351556284)
34. Thomas NE. BRAF somatic mutations in malignant melanoma and melanocyte naevi. Melanoma Res 2006;16:97-103.
35. Bao R, Lai CJ, Qu H, et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin Cancer Res 2009;15:4046-4057
36. Lundgren K, Zhang H, Brekken J, et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8:921-929
37. Kim YS, Alarcon SV, Lee S, et al. Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 2009;9:1479-1492